ERBB2 and breast cancer: Using data from 79 cancer patientsand 20 healthy donors as control, our device yielded 96% sensitivityand 100% specificity, which is comparable to other approaches relyingon a combination of capture and staining.11,51 Then we used it to identify potential responders to PD-L1 ICI therapies.In comparison to commercially available liquid biopsy approaches,in the context of nonsmall-cell lung carcinoma, our device performedfavorably.46 Finally, we validated ourapproach against clinical standards in the context of HER2 positivebreast cancer on a cohort of 26 breast cancer patients.